Evidence map›Paper›PMID 25874348›Full record

ReviewCurrent rheumatology reports2015

Cystine growth inhibition through molecular mimicry: a new paradigm for the prevention of crystal diseases.

Michael H Lee, Amrik Sahota, Michael D Ward, David S Goldfarb

Abstract readReview
In one paragraph

Review in Current rheumatology reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Development of convenient crystallization inhibition assays for structure-activity relationship studies in the discovery of crystallization inhibitors.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2023
    Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Cystinuria in Dogs and Cats: What Do We Know after Almost 200 Years?Animals : an open access journal from MDPI · 2021
    Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Michael H LeeNYU Langone Medical Center, New York, NY, USA, michael.lee@nyumc.org.
Amrik Sahota
Michael D Ward
David S Goldfarb
NYU Langone Health · USNew York University · USRutgers, The State University of New Jersey · US

Funding

Primary HyperoxaluriaU54DK083908 · NIDDK · MAYO CLINIC ROCHESTER · PI MILLINER, DAWN SCHMAUTZ · 2009 to 2018
$12.3M
NIDDK NIH HHS U54 DK083908PHS HHS U54KD083908
6 · The paper itself

Abstract

Cystinuria is a genetic disease marked by recurrent kidney stone formation, usually at a young age. It frequently leads to chronic kidney disease. Treatment options for cystinuria have been limited despite comprehensive understanding of its genetic pathophysiology. Currently available therapies suffer from either poor clinical adherence to the regimen or potentially serious adverse effects. Recently, we employed atomic force miscopy (AFM) to identify L-cystine dimethylester (CDME) as an effective molecular imposter of L-cystine, capable of inhibiting crystal growth in vitro. More recently, we demonstrated CDME's efficacy in inhibiting L-cystine crystal growth in vivo utilizing a murine model of cystinuria. The application of AFM to discover inhibitors of crystal growth through structural mimicry suggests a novel approach to preventing and treating crystal diseases.

Indexed as

Molecular MimicryAnimalsCrystallizationCystineCystinuriaDrug DesignHumansKidney CalculiMicroscopy, Atomic ForceMolecular Targeted TherapyCystineL-cystine dimethylester

Identifiers

PMID25874348
PMCPMC4518543
OpenAlexW1975415222

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.